Clinical Trial Update: A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the effects of SUL-238 on energy metabolism using 31P-MRS in patients with early, untreated Parkinson's disease and is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SUL-238 (SUL-238)

Snippet

Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş. | Conditions: Parkinson's Disease (PD) | Phase 2 | Status: RECRUITING